Plain-English translation of NCT07330778 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing a new medication called in people with mild to moderate asthma. The medication is a bispecific antibody, which is a type of engineered protein designed to target two specific pathways involved in asthma inflammation. Researchers want to understand how safe this treatment is and how it behaves in the body.
Current asthma treatments work well for many people, but researchers are always looking for new options that might help those who don't respond well enough to existing medications or have side effects. This medication targets specific immune molecules involved in asthma, which could offer a different approach to controlling asthma symptoms.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic to receive a single intravenous infusion (IV) of the medication. After that, you would have follow-up visits at the clinic through week 12 so the research team can monitor your safety and measure how your body responds to the treatment. These visits will include breathing tests and other routine checks to make sure everything is going well.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States